### I. Epidemiological profile

**Population**
- High transmission (>1 case per 1000 population): 14,500,000 (96%)
- Low transmission (≤1 cases per 1000 population): 691,000 (4%)
- Malaria-free (0 cases): 0
- Total: 15,191,000

### II. Intervention policies and strategies

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Policies/strategies</th>
<th>Yes/No</th>
<th>Adopted</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITN</td>
<td>ITN/LINL distributed free of charge</td>
<td>Yes</td>
<td>1998</td>
</tr>
<tr>
<td>IRS</td>
<td>IRS is recommended</td>
<td>Yes</td>
<td>2006</td>
</tr>
<tr>
<td>Larval control</td>
<td>Use of larval control recommended</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>IPT</td>
<td>IPT used to prevent malaria during pregnancy</td>
<td>Yes</td>
<td>2000</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Patients of all ages should receive diagnostic test</td>
<td>Yes</td>
<td>2007</td>
</tr>
<tr>
<td>Treatment</td>
<td>ACT is free for all ages in public sector</td>
<td>Yes</td>
<td>2011</td>
</tr>
<tr>
<td>Surveillance</td>
<td>ACD for case investigation (reactive)</td>
<td>Yes</td>
<td>2012</td>
</tr>
</tbody>
</table>

### III. Financing

**Sources of financing**

- Government expenditure
- Global Fund
- World Bank
- USAID/PF
- WHO/UNICEF
- Others

### IV. Coverage

#### ITN and IRS coverage

- **2015**
  - ITNs distributed: 1,400,000
  - IRS area covered: 1,400,000

#### Cases tracked

- **2015**
  - Fever cases <5 conferring treatment at public HF (survey): 7,560

#### Test positivity

- **2015**
  - Parasite prevalence rate: 9%

### V. Impact

**Confirmed malaria cases per 1000 and ABER**

- **2005**
  - ABER (microscopy & RDT): 35
  - Cases (all species): 10
  - Cases (P. falciparum): 9

**Malaria admissions and deaths (per 100,000)**

- **2005**
  - Deaths (all species): 2
  - Deaths (P. falciparum): 1

---

**World Malaria Report 2016**

**Senegal**

**African Region**

---

**Parasites and vectors**

- Major plasmodium species: P. falciparum (100%), P. vivax (8%)

**Reported confirmed cases**
- Estimated cases: 492,253
- Estimated deaths: 1,440,000

**Surveillance**

- ACD of febrile cases at community level (pro-active): Yes (2012)
- ACD for case investigation (reactive): Yes (2012)
- Surveillance system for monitoring of adverse reactions to antimalarials: Yes (2007)
- Larval control: No
- ACT as free for all ages in public sector: Yes (2011)
- Directly observed treatment with primaquine: No
- G6PD test is a requirement before treatment with primaquine: No

**Antimalaria treatment policy**

- Treatment of severe malaria: AL, AS+AQ, DHA-PPQ (2005)
- Dosage of primaquine for radical treatment of P. vivax: 15 mg base/kg daily for 14 days (2005)
- Type of RDT used: PT-only

**Therapeutic efficacy tests**

- Clinical and parasitological failure: 100% (2010–2014)
- Follow-up: Yes
- No. of studies: Yes
- Species: Plasmodium falciparum

**Insecticide susceptibility bioassays**

- Reporting resistance to at least one insecticide for any vector at any locality: Yes

---

**Government expenditure by intervention in 2015**

- Antimalarial medicines
- Insecticides & spray materials
- Diagnostic testing
- Antimalarial medicines
- Human resources & technical assistance
- Management and other costs

---

**Cases tested and treated in public sector**

- **2015**
  - Cases tested: 74,580
  - Cases treated: 74,580

---

**Destination contribution to APDL Parasite Prevalence (PP)**